WELCOME TO
RNAiScience Data Hall
This website was created for healthcare professionals to provide access to educational and scientific information about Alnylam's RNAi platform and our data from congresses and publications.
Therapeutic Areas
Science of RNAi
Video
RNAi Mechanism of Action
This video highlights the mechanism of action (MOA) of RNAi therapeutics and its role in silencing gene expression. This video is intended to be viewed in its entirety.
Congresses
Primary Hyperoxaluria Type 1 (PH1)
Oxalosis & Hyperoxaluria Foundation (OHF) 2026
Transthyretin Amyloidosis (ATTR)
RNA Therapeutics Symposium (RNATx) 2026
Publications
Transthyretin Amyloidosis (ATTR)
Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial
European Journal of Heart Failure
Transthyretin Amyloidosis (ATTR)
Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis
Clinical Pharmacokinetics
Connect with Alnylam Medical
For further information or questions related to Alnylam's clinical data, connect with Alnylam Medical.
Medical Information
For Medical Information inquiries, please submit your question using the email below.
For country-specific Medical Information contact details, please navigate to the individual country sites located at Alnylam.com.
Adverse Events/Product Complaints
To report an adverse event or to submit a product complaint, please use the email below.
For country-specific contact details, please navigate to the individual country sites located at Alnylam.com.
Clinical Trials
For clinical trial inquiries, please use the contact options below.
